Who
David Lamond
Director
Company insider
Files Form 4 as: Director, Quince Therapeutics; Director, Lucira Health; Director, Applied Molecular Transport.
In numbers
- Trades disclosed
- 66
- Buys
- 22
- Sells
- 0
- Bought
- $9.9M
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 13 May 2019
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,700 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,700 at $0.00 | filing |
| 2 Jan 2026filed 21 Jan 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,423 at $0.00 | filing |
| 2 Jan 2026filed 21 Jan 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,423 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 2 Jan 2025filed 8 Jan 2025 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,587 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 14 Dec 2023filed 14 Dec 2023 | Quince TherapeuticsBiotechnology | SEC FORM 4 Bought | $24K22,627 at $1.04 | filing |
| 13 Dec 2023filed 14 Dec 2023 | Quince TherapeuticsBiotechnology | SEC FORM 4 Bought | $23K22,627 at $1.00 | filing |
| 12 Dec 2023filed 14 Dec 2023 | Quince TherapeuticsBiotechnology | SEC FORM 4 Bought | $300300 at $1.00 | filing |
| 12 Dec 2023filed 14 Dec 2023 | Quince TherapeuticsBiotechnology | SEC FORM 4 Bought | $23K22,327 at $1.02 | filing |
| 7 Dec 2023filed 7 Dec 2023 | Quince TherapeuticsBiotechnology | SEC FORM 4 Bought | $19K19,123 at $1.01 | filing |
| 6 Dec 2023filed 7 Dec 2023 | Quince TherapeuticsBiotechnology | SEC FORM 4 Bought | $20K19,123 at $1.02 | filing |
| 5 Dec 2023filed 7 Dec 2023 | Quince TherapeuticsBiotechnology | SEC FORM 4 Bought | $19K19,123 at $1.01 | filing |
| 1 Dec 2023filed 1 Dec 2023 | Quince TherapeuticsBiotechnology | SEC FORM 4 Bought | $14K14,378 at $0.94 | filing |
| 30 Nov 2023filed 1 Dec 2023 | Quince TherapeuticsBiotechnology | SEC FORM 4 Bought | $13K14,378 at $0.90 | filing |
| 29 Nov 2023filed 1 Dec 2023 | Quince TherapeuticsBiotechnology | SEC FORM 4 Bought | $14K14,378 at $0.98 | filing |
| 31 Aug 2023filed 31 Aug 2023 | Quince TherapeuticsBiotechnology | SEC FORM 4 Bought | $54K41,026 at $1.32 | filing |
| 30 Aug 2023filed 31 Aug 2023 | Quince TherapeuticsBiotechnology | SEC FORM 4 Bought | $54K41,026 at $1.31 | filing |
| 17 Aug 2023filed 17 Aug 2023 | Quince TherapeuticsBiotechnology | SEC FORM 4 Bought | $32K24,766 at $1.29 | filing |
News
IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst ConferenceIRLA · manilatimes.net · 15 Oct 2026
0 headlines in the last 90 days name David Lamond; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.